SOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG Research

SOPHiA GENETICS (NASDAQ:SOPH)‘s stock had its “buy” rating reaffirmed by BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s price objective suggests a potential upside of 57.79% from the company’s previous close.

Several other analysts have also recently commented on the stock. Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Stock Down 4.2%

SOPH stock opened at $5.07 on Wednesday. The stock has a market capitalization of $347.24 million, a P/E ratio of -9.94 and a beta of 1.01. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. SOPHiA GENETICS has a one year low of $2.59 and a one year high of $5.70. The company has a 50 day moving average price of $4.82 and a two-hundred day moving average price of $4.78.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Insider Activity

In other news, CEO Jurgi Camblong sold 17,473 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00. Following the completion of the sale, the chief executive officer directly owned 3,646,967 shares of the company’s stock, valued at $18,234,835. The trade was a 0.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 193,859 shares of company stock worth $943,777. 4.88% of the stock is owned by insiders.

Institutional Trading of SOPHiA GENETICS

Several institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. Akre Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the period. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Alta Wealth Advisors LLC purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at $6,708,000. Finally, Archon Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after buying an additional 14,342 shares during the period. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.